Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria: * Patients who have consented to participation in the trial. * Patients of both sexes aged between 18 and 75 years. * Patients with relapsed or refractory solid tumors who have failed available standard therapy or are not candidates for standard therapy. * Patients who are willing to provide fresh or archival biopsy material before their participation to identify the integrin expression levels (for Phase Ib only). * Patients who completed the previous treatments 21 days before the first dose of the study drug. * Patients who have at least three months of life expectancy. * Patients with ECOG performance score 0 to 1. * Patients with adequate organ function defined as: * Hemoglobin ≥10 mg/dl * Neutrophil ≥1,500/µL * Platelet ≥100,000/µL * Creatinine ≤1.5xULN or creatinine clearance ≥60mL/sec/1.73m2 * Total bilirubin ≤ 1.5xULN * AST/ALT ≤2.5xULN; for patients who have confirmed liver metastasis: AST/ALT ≤5xULN. * Prothrombin time ≤1.5xULN (in case of no anticoagulant treatment). * Normal levels of serum magnesium and potassium concentrations Exclusion Criteria: * Patients with active and/or uncontrolled central nervous system (CNS) metastasis. * Patients who have interstitial lung disease or interstitial pneumonia. * Patients who have serious cardiac dysfunction. * Patients who have insufficient target organ function. * Patients with positive tests for HAV, HBV, HCV or HIV. * Patients who experienced grade 3 or higher toxicity related to …